Chen Zhihan, Dai Yunfeng, Gao Fei, Liu Jianwen, He Juanjuan, Zhang Li, Wu Yanfang
Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
Department of Rheumatology, Fujian Provincial Hospital, Fuzhou, China.
Int J Immunopathol Pharmacol. 2025 Jan-Dec;39:3946320251331842. doi: 10.1177/03946320251331842. Epub 2025 Apr 29.
Systemic lupus erythematosus (SLE) patients are at greater risk of developing osteoporosis (OP) than the general population. This study aimed to identify crosstalk genes between SLE and OP and to validate their diagnostic accuracy as biomarkers. Data analysis based on Gene Expression Omnibus (GEO) datasets was conducted. We utilized Weighted Gene Co-Expression Network Analysis (WGCNA) and differential expression analysis to identify crosstalk genes (CGs). Machine learning algorithms and consensus clustering were applied to screen shared diagnostic biomarkers and construct two predictive models featuring key genes. We also investigated potential subgroups, immune infiltration across different subtypes, and validated hub mRNAs using quantitative real-time PCR (qPCR). Molecular docking was performed to simulate the interaction of a small molecule compound with its target. We identified 19 CGs and developed two predictive models: the IL1R2-GADD45B and CHI3L1-IL1R2-SPTLC2 diagnostic score thresholds. The CHI3L1-IL1R2-SPTLC2 model showed improved predictive accuracy for lupus-associated osteoporosis. The C2 subtype was found to potentially regulate bone metabolism in SLE patients. Immune infiltration analysis indicated a strong association between CGs and multiple immunocytes, with IL1R2 being a common element in both models. Molecular docking suggests that Anakinra's therapeutic effect may involve IL1R2. Our study introduces novel diagnostic biomarkers and predictive models for lupus-associated osteoporosis, with a particular focus on IL1R2 as an innovative biomarker and therapeutic target. These are anticipated to aid early screening and risk assessment in SLE patients, pending large-scale clinical validation.
系统性红斑狼疮(SLE)患者比普通人群患骨质疏松症(OP)的风险更高。本研究旨在识别SLE和OP之间的串扰基因,并验证其作为生物标志物的诊断准确性。基于基因表达综合数据库(GEO)数据集进行了数据分析。我们利用加权基因共表达网络分析(WGCNA)和差异表达分析来识别串扰基因(CGs)。应用机器学习算法和一致性聚类来筛选共享诊断生物标志物,并构建两个以关键基因为特征的预测模型。我们还研究了潜在亚组、不同亚型间的免疫浸润,并使用定量实时PCR(qPCR)验证了核心mRNA。进行分子对接以模拟小分子化合物与其靶点的相互作用。我们识别出19个CGs,并开发了两个预测模型:IL1R2 - GADD45B和CHI3L1 - IL1R2 - SPTLC2诊断评分阈值。CHI3L1 - IL1R2 - SPTLC2模型对狼疮相关性骨质疏松症显示出更高的预测准确性。发现C2亚型可能调节SLE患者的骨代谢。免疫浸润分析表明CGs与多种免疫细胞之间存在密切关联,IL1R2是两个模型中的共同元素。分子对接表明阿那白滞素的治疗作用可能涉及IL1R2。我们的研究引入了用于狼疮相关性骨质疏松症的新型诊断生物标志物和预测模型,特别关注IL1R2作为一种创新生物标志物和治疗靶点。在大规模临床验证之前,预计这些将有助于SLE患者的早期筛查和风险评估。